OBJECTIVE To examine the therapeutic effects and toxicity of high-dose-folinic acid plus a 5-fluorouracil(5-FU)bolus and continuous infusion with 5-FU combined with locally produced oxaliplatin(L-HOP)in treating advan...OBJECTIVE To examine the therapeutic effects and toxicity of high-dose-folinic acid plus a 5-fluorouracil(5-FU)bolus and continuous infusion with 5-FU combined with locally produced oxaliplatin(L-HOP)in treating advanced gastric carcinoma patients. METHODS Sixty-five patients with advanced gastric carcinoma were treated with high-dose-folinic acid plus a 5-FU bolus and a 48-h continuous infusion of 5-FU combined with oxaliplatin.The effects of treatment and toxicity were observed. RESULTS There were 4 complete responses,26 partial responses, 30 with no change and 5 with progressive disease.The overall effective response rate was 46.2%(30/65).The median duration was 7 months,with the main side effects including nausea and vomiting,peripheral phlebitis,alopecia,leukopenia,dental ulcers, peripheral neuritis and diarrhea.All the side effects were tolerated and minimal. CONCLUSION The results showed that high-dose folinic acid plus a 5-FU bolus and continuous infusion of 5-FU combined with oxaliplatin appears to be a safe and effective therapy for patients with advanced gastric carcinoma.This therapeutic regimen is of value for these patients.展开更多
Objective: The aim of this study was to evaluate the efficacy and toxicity of modified docetaxel, cisplatin and calcium folinate (CF)/5-fluorouracil (mDCF) combination therapy for 27 patients with recurrent or metasta...Objective: The aim of this study was to evaluate the efficacy and toxicity of modified docetaxel, cisplatin and calcium folinate (CF)/5-fluorouracil (mDCF) combination therapy for 27 patients with recurrent or metastatic gastric adeno- carcinoma (R/MGC). Methods: From May 2006 to July 2007, 27 R/MGC patients (18 were male and 9 were female) with a median age of 49 years (range19-66) were consecutively enrolled. The mDCF protocol included 50 mg/m2 docetaxel for 1 day and 25 mg/m2 cisplatin on d2-3, 200 mg/m2 CF on d2-3 and 2000 mg/m2 5-fluorouracil (5-FU) CIV (continous infusion) for 46 h on d2-3, repeated every 2 weeks. Results: Twenty-seven patients were evaluable for efficacy and toxicity. A median of 4.5 cycles was given. One complete and 12 partial responses were observed for an overall intent to treat response rate (RR) 48.1% [95% CI (confidence intervals): 32%-64%]. Median time-to-progression (TTP) was 6.2 months and overall survival (OS) was 11.8 months. Twenty-seven (100%) patients experienced bone marrow suppression, and of them 48.9% were Grade 3-4 (16.3% were Grade 4). Two patients (7.4%) ceased chemotherapy because of bone marrow suppression. WHO Grade 1-4 non-hematological toxicity, such as oral mucositis, nausea/emesia, peripheral neuropathy, liver dysfunction, diarrhea, nephrotoxicity and cardiotoxicity, occurred in 59.2%、51.9%, 48.1%, 44.4%, 25.9%, 18.5% and 11.1% patients, respectively, and most of them were Grade 1-2. No patient died due to chemotherapy toxicity. Conclusion: mDCF regimen is effective in treating R/MGC with a high RR and long TTP/OS in this trial. Despite its severe hematotoxicity, this regimen has some advantages such as no cross-resistance with paclitaxel (paclitaxel-resistant patients RR 2/6). These results suggested that the mDCF regimen worth further investigation in clinical study of R/MGC treatment.展开更多
背景目前国内外对高剂量甲氨蝶呤(MTX)排泄延迟是否应该使用血液透析解救还存在争议。目的研究高通量血液透析(HF-HD)对肿瘤患儿MTX清除的有效性。设计病例系列报告。方法纳入2016年1月至2021年6月在上海交通大学医学院附属上海儿童医...背景目前国内外对高剂量甲氨蝶呤(MTX)排泄延迟是否应该使用血液透析解救还存在争议。目的研究高通量血液透析(HF-HD)对肿瘤患儿MTX清除的有效性。设计病例系列报告。方法纳入2016年1月至2021年6月在上海交通大学医学院附属上海儿童医学中心血液肿瘤科行MTX化疗后44 h血药浓度>10μmol·L-1的连续病例,其中仅使用亚叶酸钙(CF)解救的患儿为非HF-HD组,使用HF-HD+CF解救的患儿为HF-HD组。比较2组患儿的胃肠道、肝功能、肾功能和血液系统毒性等指标。主要结局指标肝、肾功能不良反应发生率。结果20例发生20例次MTX延迟排泄,非HF-HD组9例,HF-HD组11例,两组患儿美国卫生及公共服务部常见不良事件评价标准v 4.0项目比较,CF组和HF-HD组肌酐、尿酸、ALT、AST、黏膜炎、24 h MTX浓度、MTX浓度恢复正常所需的时间差异均无统计学意义,两组患儿血液系统不良反应发生率差异无统计学意义(P>0.05);AST、ALT、发热、黏膜炎、WBC、NE、Hb、PLT异常发生率两组差异无统计学意义。结论肾功能正常的肿瘤患儿通过CF解救可有效安全清除MTX,非必要不选择透析。展开更多
文摘OBJECTIVE To examine the therapeutic effects and toxicity of high-dose-folinic acid plus a 5-fluorouracil(5-FU)bolus and continuous infusion with 5-FU combined with locally produced oxaliplatin(L-HOP)in treating advanced gastric carcinoma patients. METHODS Sixty-five patients with advanced gastric carcinoma were treated with high-dose-folinic acid plus a 5-FU bolus and a 48-h continuous infusion of 5-FU combined with oxaliplatin.The effects of treatment and toxicity were observed. RESULTS There were 4 complete responses,26 partial responses, 30 with no change and 5 with progressive disease.The overall effective response rate was 46.2%(30/65).The median duration was 7 months,with the main side effects including nausea and vomiting,peripheral phlebitis,alopecia,leukopenia,dental ulcers, peripheral neuritis and diarrhea.All the side effects were tolerated and minimal. CONCLUSION The results showed that high-dose folinic acid plus a 5-FU bolus and continuous infusion of 5-FU combined with oxaliplatin appears to be a safe and effective therapy for patients with advanced gastric carcinoma.This therapeutic regimen is of value for these patients.
文摘Objective: The aim of this study was to evaluate the efficacy and toxicity of modified docetaxel, cisplatin and calcium folinate (CF)/5-fluorouracil (mDCF) combination therapy for 27 patients with recurrent or metastatic gastric adeno- carcinoma (R/MGC). Methods: From May 2006 to July 2007, 27 R/MGC patients (18 were male and 9 were female) with a median age of 49 years (range19-66) were consecutively enrolled. The mDCF protocol included 50 mg/m2 docetaxel for 1 day and 25 mg/m2 cisplatin on d2-3, 200 mg/m2 CF on d2-3 and 2000 mg/m2 5-fluorouracil (5-FU) CIV (continous infusion) for 46 h on d2-3, repeated every 2 weeks. Results: Twenty-seven patients were evaluable for efficacy and toxicity. A median of 4.5 cycles was given. One complete and 12 partial responses were observed for an overall intent to treat response rate (RR) 48.1% [95% CI (confidence intervals): 32%-64%]. Median time-to-progression (TTP) was 6.2 months and overall survival (OS) was 11.8 months. Twenty-seven (100%) patients experienced bone marrow suppression, and of them 48.9% were Grade 3-4 (16.3% were Grade 4). Two patients (7.4%) ceased chemotherapy because of bone marrow suppression. WHO Grade 1-4 non-hematological toxicity, such as oral mucositis, nausea/emesia, peripheral neuropathy, liver dysfunction, diarrhea, nephrotoxicity and cardiotoxicity, occurred in 59.2%、51.9%, 48.1%, 44.4%, 25.9%, 18.5% and 11.1% patients, respectively, and most of them were Grade 1-2. No patient died due to chemotherapy toxicity. Conclusion: mDCF regimen is effective in treating R/MGC with a high RR and long TTP/OS in this trial. Despite its severe hematotoxicity, this regimen has some advantages such as no cross-resistance with paclitaxel (paclitaxel-resistant patients RR 2/6). These results suggested that the mDCF regimen worth further investigation in clinical study of R/MGC treatment.
文摘背景目前国内外对高剂量甲氨蝶呤(MTX)排泄延迟是否应该使用血液透析解救还存在争议。目的研究高通量血液透析(HF-HD)对肿瘤患儿MTX清除的有效性。设计病例系列报告。方法纳入2016年1月至2021年6月在上海交通大学医学院附属上海儿童医学中心血液肿瘤科行MTX化疗后44 h血药浓度>10μmol·L-1的连续病例,其中仅使用亚叶酸钙(CF)解救的患儿为非HF-HD组,使用HF-HD+CF解救的患儿为HF-HD组。比较2组患儿的胃肠道、肝功能、肾功能和血液系统毒性等指标。主要结局指标肝、肾功能不良反应发生率。结果20例发生20例次MTX延迟排泄,非HF-HD组9例,HF-HD组11例,两组患儿美国卫生及公共服务部常见不良事件评价标准v 4.0项目比较,CF组和HF-HD组肌酐、尿酸、ALT、AST、黏膜炎、24 h MTX浓度、MTX浓度恢复正常所需的时间差异均无统计学意义,两组患儿血液系统不良反应发生率差异无统计学意义(P>0.05);AST、ALT、发热、黏膜炎、WBC、NE、Hb、PLT异常发生率两组差异无统计学意义。结论肾功能正常的肿瘤患儿通过CF解救可有效安全清除MTX,非必要不选择透析。